All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

cefuroxime 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	565	55268-75-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefuroxime biofuroxim cefaloxime cefasyn cefuroxim cefuroxime acid cephuroxime cefuroxime sodium cefuroxime sodium salt	Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS. Molecular weight: 424.38 Formula: C16H16N4O8S CLOGP: 0.44 LIPINSKI: 1 HAC: 12 HDO: 3 TPSA: 173.76 ALOGS: -3.17 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	O
3	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	89 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	96 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	39.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	32 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.15 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.20 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 19, 1983	FDA	COVIS INJECTABLES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	253.09	12.86	127	17971	23506	63447418
Anaphylactic reaction	241.28	12.86	178	17920	65922	63405002
Macular oedema	145.60	12.86	51	18047	3826	63467098
Retinal detachment	141.44	12.86	56	18042	5913	63465011
Corneal oedema	111.03	12.86	33	18065	1460	63469464
Bronchospasm	87.57	12.86	57	18041	17223	63453701
Patent ductus arteriosus	87.35	12.86	36	18062	4214	63466710
Type IV hypersensitivity reaction	85.87	12.86	32	18066	2866	63468058
Foetal exposure during pregnancy	83.99	12.86	71	18027	31891	63439033
Premature baby	82.74	12.86	59	18039	20676	63450248
Corneal opacity	80.38	12.86	22	18076	721	63470203
Exposure during pregnancy	78.69	12.86	151	17947	155396	63315528
Drug reaction with eosinophilia and systemic symptoms	74.55	12.86	68	18030	33768	63437156
Retinal oedema	67.75	12.86	19	18079	682	63470242
Anterior chamber inflammation	66.43	12.86	16	18082	311	63470613
Type I hypersensitivity	64.14	12.86	26	18072	2916	63468008
Rash maculo-papular	62.38	12.86	60	18038	31836	63439088
Endophthalmitis	59.14	12.86	26	18072	3566	63467358
Joint swelling	53.01	12.86	14	18084	327652	63143272
Parophthalmia	51.45	12.86	13	18085	310	63470614
Alopecia	49.92	12.86	17	18081	337519	63133405
Retinal toxicity	48.74	12.86	17	18081	1258	63469666
Premature delivery	48.28	12.86	51	18047	30230	63440694
Accidental overdose	47.77	12.86	45	18053	23264	63447660
Dysbiosis	46.19	12.86	15	18083	891	63470033
Cataract operation complication	45.28	12.86	10	18088	130	63470794
Premature rupture of membranes	45.24	12.86	24	18074	4969	63465955
Cystoid macular oedema	45.24	12.86	17	18081	1558	63469366
Low birth weight baby	44.89	12.86	27	18071	7102	63463822
Systemic lupus erythematosus	44.84	12.86	4	18094	208914	63262010
Rheumatoid arthritis	44.71	12.86	9	18089	253810	63217114
Angioedema	43.96	12.86	61	18037	47904	63423020
Cross sensitivity reaction	43.36	12.86	18	18080	2144	63468780
Retinopathy	43.17	12.86	20	18078	3099	63467825
Corneal deposits	42.59	12.86	11	18087	287	63470637
Arthropathy	42.03	12.86	8	18090	234784	63236140
Clostridium difficile infection	41.78	12.86	47	18051	29875	63441049
Drug interaction	41.07	12.86	151	17947	228980	63241944
Resuscitation	38.97	12.86	14	18084	1130	63469794
Swelling	38.79	12.86	15	18083	275363	63195561
Infusion related reaction	38.73	12.86	11	18087	245510	63225414
Visual acuity reduced	37.01	12.86	38	18060	21788	63449136
Congenital tricuspid valve incompetence	36.97	12.86	8	18090	94	63470830
Circulatory collapse	36.85	12.86	38	18060	21900	63449024
Kounis syndrome	36.72	12.86	15	18083	1715	63469209
Multiple organ dysfunction syndrome	36.20	12.86	61	18037	56691	63414233
Toxic epidermal necrolysis	35.72	12.86	40	18058	25294	63445630
Hypotension	35.66	12.86	163	17935	272441	63198483
Meningitis candida	35.24	12.86	7	18091	52	63470872
Treatment failure	35.16	12.86	7	18091	199036	63271888
Congenital pulmonary hypertension	34.67	12.86	7	18091	57	63470867
Pneumonia mycoplasmal	34.08	12.86	12	18086	913	63470011
Therapeutic product effect decreased	33.70	12.86	7	18091	193180	63277744
Conjunctival oedema	33.28	12.86	11	18087	691	63470233
Airway peak pressure increased	33.14	12.86	9	18089	286	63470638
Toxic anterior segment syndrome	33.03	12.86	14	18084	1757	63469167
Trimethylaminuria	32.76	12.86	8	18090	165	63470759
Lip swelling	32.27	12.86	42	18056	31021	63439903
Contraindicated product administered	32.09	12.86	11	18087	217637	63253287
Fatigue	31.79	12.86	138	17960	887890	62583034
Drug intolerance	31.64	12.86	25	18073	308636	63162288
Toxoplasmosis	31.63	12.86	13	18085	1510	63469414
Foetal non-stress test abnormal	31.61	12.86	6	18092	34	63470890
Musculoskeletal stiffness	31.56	12.86	7	18091	184611	63286313
Face oedema	30.38	12.86	33	18065	20179	63450745
Cardiac massage	29.70	12.86	5	18093	12	63470912
Stevens-Johnson syndrome	29.52	12.86	36	18062	24914	63446010
Anterior chamber fibrin	29.38	12.86	6	18092	52	63470872
Cardiovascular insufficiency	28.91	12.86	12	18086	1429	63469495
Urticaria	28.62	12.86	108	17990	165694	63305230
Pseudomembranous colitis	28.31	12.86	15	18083	3097	63467827
Product monitoring error	28.17	12.86	17	18081	4499	63466425
Tachypnoea	27.32	12.86	29	18069	17273	63453651
Pain	27.13	12.86	114	17984	740514	62730410
Pericarditis	26.96	12.86	3	18095	131576	63339348
Joint hyperextension	26.80	12.86	8	18090	359	63470565
Blood pressure decreased	26.74	12.86	58	18040	64964	63405960
Antidiuretic hormone abnormality	26.70	12.86	5	18093	26	63470898
Sepsis syndrome	26.45	12.86	10	18088	932	63469992
Drug hypersensitivity	26.39	12.86	165	17933	310522	63160402
Nephritis allergic	25.98	12.86	7	18091	216	63470708
Boutonneuse fever	25.88	12.86	4	18094	4	63470920
Vulval cancer metastatic	25.88	12.86	4	18094	4	63470920
Macular ischaemia	25.56	12.86	5	18093	34	63470890
Linear IgA disease	25.51	12.86	11	18087	1440	63469484
Oesophageal spasm	25.47	12.86	14	18084	3109	63467815
Discomfort	25.47	12.86	8	18090	167366	63303558
Staphylococcal sepsis	25.44	12.86	20	18078	8108	63462816
Ocular toxicity	25.36	12.86	9	18089	701	63470223
Hypopyon	25.09	12.86	9	18089	723	63470201
Clostridium difficile colitis	24.85	12.86	30	18068	20539	63450385
Arthralgia	23.86	12.86	83	18015	569627	62901297
Oliguria	23.45	12.86	20	18078	9081	63461843
Oesophageal pain	23.26	12.86	14	18084	3687	63467237
Renal failure	23.15	12.86	80	18018	117572	63353352
Toxic skin eruption	22.88	12.86	23	18075	12862	63458062
Weight increased	22.16	12.86	25	18073	260767	63210157
Jaundice	22.14	12.86	34	18064	29217	63441707
Tachycardia	22.09	12.86	79	18019	118077	63352847
Restlessness	21.97	12.86	34	18064	29419	63441505
Hyperleukocytosis	21.89	12.86	8	18090	678	63470246
Erythema	21.41	12.86	103	17995	175648	63295276
Pyroglutamate increased	21.27	12.86	7	18091	434	63470490
Wound	21.20	12.86	10	18088	163253	63307671
Abdominal discomfort	21.06	12.86	37	18061	320848	63150076
Bulimia nervosa	20.77	12.86	7	18091	467	63470457
Foetal anaemia	20.77	12.86	5	18093	97	63470827
Nosocomial infection	20.64	12.86	10	18088	1711	63469213
Merycism	19.98	12.86	6	18092	275	63470649
Product preparation issue	19.87	12.86	9	18089	1323	63469601
Vanishing twin syndrome	19.80	12.86	5	18093	119	63470805
Sepsis	19.57	12.86	91	18007	153032	63317892
Delayed delivery	19.35	12.86	4	18094	37	63470887
Idiopathic angioedema	19.26	12.86	4	18094	38	63470886
Natural killer cell count decreased	19.07	12.86	4	18094	40	63470884
Hydronephrosis	18.87	12.86	19	18079	10643	63460281
Colitis ischaemic	18.80	12.86	19	18079	10689	63460235
Acute kidney injury	18.79	12.86	134	17964	263281	63207643
Exophthalmos	18.76	12.86	9	18089	1507	63469417
Cutaneous vasculitis	18.76	12.86	14	18084	5255	63465669
Hepatic enzyme increased	18.76	12.86	18	18080	202310	63268614
Coma blister	18.53	12.86	5	18093	155	63470769
Tinnitus	18.48	12.86	35	18063	35593	63435331
Retroplacental haematoma	18.41	12.86	5	18093	159	63470765
Serous retinal detachment	18.40	12.86	6	18092	361	63470563
Pyelonephritis	18.40	12.86	24	18074	17754	63453170
Anaphylactoid reaction	18.17	12.86	12	18086	3711	63467213
Maculopathy	18.06	12.86	10	18088	2252	63468672
Eye inflammation	18.00	12.86	14	18084	5585	63465339
Intentional product use issue	17.93	12.86	7	18091	127885	63343039
Mediastinal effusion	17.71	12.86	4	18094	58	63470866
Moraxella infection	17.24	12.86	6	18092	441	63470483
Retinal infarction	17.22	12.86	4	18094	66	63470858
Hepatitis toxic	17.14	12.86	11	18087	3242	63467682
Pneumonia	17.06	12.86	202	17896	456565	63014359
Congenital lymphoedema	16.67	12.86	3	18095	12	63470912
Pupillary block	16.67	12.86	3	18095	12	63470912
Dermatitis allergic	16.54	12.86	21	18077	15127	63455797
Delivery	16.37	12.86	8	18090	1395	63469529
Bradycardia	16.36	12.86	52	18046	73175	63397749
Cerebral mass effect	16.31	12.86	7	18091	906	63470018
Anaemia of malignant disease	16.19	12.86	6	18092	529	63470395
Deafness bilateral	16.16	12.86	8	18090	1434	63469490
Coagulation time prolonged	16.13	12.86	8	18090	1440	63469484
Stenosis	16.10	12.86	8	18090	1446	63469478
Neonatal respiratory distress syndrome	16.02	12.86	10	18088	2808	63468116
Lower respiratory tract infection	15.84	12.86	9	18089	132298	63338626
Toxicity to various agents	15.78	12.86	29	18069	247221	63223703
Vitreous disorder	15.69	12.86	4	18094	99	63470825
Live birth	15.61	12.86	27	18071	25603	63445321
Acinetobacter infection	15.45	12.86	8	18090	1575	63469349
Lip oedema	15.27	12.86	11	18087	3913	63467011
B-lymphocyte count increased	15.02	12.86	4	18094	118	63470806
Retinal disorder	14.96	12.86	8	18090	1682	63469242
Blood creatinine increased	14.95	12.86	57	18041	87787	63383137
Gestational diabetes	14.93	12.86	15	18083	8381	63462543
Intermittent positive pressure breathing	14.91	12.86	3	18095	24	63470900
Cardiac arrest	14.90	12.86	59	18039	92486	63378438
Tubulointerstitial nephritis	14.88	12.86	23	18075	19880	63451044
Hypersensitivity vasculitis	14.80	12.86	11	18087	4101	63466823
Urticaria contact	14.80	12.86	3	18095	25	63470899
Cyanosis	14.71	12.86	21	18077	16914	63454010
Shock	14.66	12.86	25	18073	23438	63447486
Spinal muscular atrophy	14.59	12.86	3	18095	27	63470897
Abortion late	14.50	12.86	4	18094	135	63470789
Nasopharyngitis	14.36	12.86	32	18066	254225	63216699
HER2 positive breast cancer	14.32	12.86	5	18093	371	63470553
Cholestatic liver injury	14.18	12.86	9	18089	2601	63468323
Hepatosplenomegaly	14.17	12.86	9	18089	2605	63468319
Gait disturbance	14.04	12.86	19	18079	183159	63287765
Lymphoedema	14.04	12.86	17	18081	11675	63459249
Brain compression	13.90	12.86	5	18093	405	63470519
Product prescribing error	13.85	12.86	26	18072	26263	63444661
Cogwheel rigidity	13.82	12.86	8	18090	1962	63468962
Enanthema	13.71	12.86	5	18093	421	63470503
Sinobronchitis	13.68	12.86	4	18094	167	63470757
Hypotonia	13.67	12.86	15	18083	9270	63461654
Disturbance in attention	13.40	12.86	32	18066	38157	63432767
Fall	13.33	12.86	62	18036	392272	63078652
Pelvic fluid collection	13.33	12.86	6	18092	870	63470054
Hallucination	13.24	12.86	40	18058	54777	63416147
Normal newborn	13.20	12.86	14	18084	8327	63462597
Nail avulsion	13.12	12.86	4	18094	193	63470731
Paranasal sinus inflammation	12.98	12.86	5	18093	490	63470434
Intraocular pressure increased	12.96	12.86	12	18086	6066	63464858
Metabolic acidosis	12.94	12.86	35	18063	45034	63425890
Arteriospasm coronary	12.93	12.86	10	18088	3958	63466966

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Type IV hypersensitivity reaction	162.34	14.92	48	14788	1386	34940709
Anaphylactic reaction	139.40	14.92	113	14723	32188	34909907
Anaphylactic shock	129.54	14.92	82	14754	15859	34926236
Lung consolidation	120.29	14.92	56	14780	5880	34936215
Soft tissue mass	89.23	14.92	28	14808	991	34941104
Multimorbidity	87.17	14.92	27	14809	915	34941180
Rash maculo-papular	83.50	14.92	80	14756	28371	34913724
Oesophageal perforation	80.76	14.92	27	14809	1172	34940923
Retinal infarction	79.84	14.92	17	14819	118	34941977
Retinal toxicity	78.38	14.92	21	14815	419	34941676
Macular oedema	76.64	14.92	33	14803	2881	34939214
Spinal muscular atrophy	71.01	14.92	19	14817	377	34941718
Pyrexia	70.30	14.92	303	14533	332710	34609385
Superinfection	67.81	14.92	29	14807	2490	34939605
Drug reaction with eosinophilia and systemic symptoms	66.65	14.92	76	14760	32936	34909159
Inflammatory marker increased	65.08	14.92	35	14801	4993	34937102
Resuscitation	64.51	14.92	24	14812	1429	34940666
Pneumococcal sepsis	62.53	14.92	22	14814	1115	34940980
Macular detachment	60.12	14.92	13	14823	98	34941997
Endophthalmitis	58.62	14.92	29	14807	3479	34938616
Transplant failure	58.27	14.92	29	14807	3524	34938571
Stoma closure	57.75	14.92	15	14821	264	34941831
Retinal detachment	57.39	14.92	33	14803	5358	34936737
Ocular toxicity	55.15	14.92	14	14822	224	34941871
Toxic epidermal necrolysis	54.49	14.92	56	14780	21590	34920505
Corneal oedema	51.63	14.92	20	14816	1331	34940764
Motor neurone disease	48.60	14.92	15	14821	502	34941593
Lymphadenectomy	48.41	14.92	14	14822	373	34941722
Rales	47.79	14.92	37	14799	9846	34932249
Ischaemic cerebral infarction	46.02	14.92	18	14818	1229	34940866
Retinal oedema	45.27	14.92	15	14821	633	34941462
Increased bronchial secretion	45.23	14.92	20	14816	1861	34940234
Bronchial disorder	43.96	14.92	18	14818	1385	34940710
Sputum increased	43.83	14.92	21	14815	2349	34939746
Anticoagulation drug level above therapeutic	42.98	14.92	20	14816	2096	34939999
Clostridium difficile colitis	41.96	14.92	42	14794	15688	34926407
Immunosuppressant drug level increased	41.47	14.92	28	14808	6027	34936068
Lower respiratory tract infection bacterial	40.69	14.92	13	14823	488	34941607
Injury	40.68	14.92	47	14789	20640	34921455
Respiratory tract infection bacterial	39.82	14.92	18	14818	1764	34940331
Metabolic disorder	39.77	14.92	24	14812	4259	34937836
Bronchospasm	38.93	14.92	34	14802	10697	34931398
Oesophageal carcinoma	38.93	14.92	32	14804	9272	34932823
Lack of spontaneous speech	38.72	14.92	8	14828	47	34942048
Disease complication	38.10	14.92	20	14816	2716	34939379
Chest X-ray abnormal	36.64	14.92	23	14813	4375	34937720
Tachypnoea	36.60	14.92	42	14794	18310	34923785
Pathogen resistance	36.34	14.92	31	14805	9451	34932644
Death	35.00	14.92	73	14763	397976	34544119
Foetal exposure during pregnancy	34.91	14.92	60	14776	38041	34904054
Pulmonary vasculitis	34.51	14.92	12	14824	587	34941508
Intestinal intraepithelial lymphocytes increased	34.51	14.92	9	14827	161	34941934
Clostridium difficile infection	33.95	14.92	41	14795	18857	34923238
Kounis syndrome	33.91	14.92	18	14818	2500	34939595
Small for dates baby	33.89	14.92	21	14815	3906	34938189
Congenital pneumonia	33.80	14.92	8	14828	94	34942001
Intestinal ischaemia	33.01	14.92	27	14809	7767	34934328
Renal injury	31.92	14.92	31	14805	11164	34930931
Escherichia infection	31.69	14.92	27	14809	8218	34933877
Cryptitis	31.59	14.92	9	14827	227	34941868
Nervous system neoplasm	30.32	14.92	8	14828	150	34941945
Myocardial ischaemia	30.03	14.92	37	14799	17371	34924724
Neuritis	29.32	14.92	12	14824	922	34941173
Motor dysfunction	29.21	14.92	24	14812	6950	34935145
Inflammation	29.18	14.92	47	14789	28248	34913847
Biopsy	29.08	14.92	9	14827	304	34941791
Microvillous inclusion disease	28.46	14.92	8	14828	192	34941903
Haemoptysis	28.05	14.92	52	14784	34954	34907141
Brain injury	27.54	14.92	22	14814	6120	34935975
Pneumonia	27.00	14.92	253	14583	362374	34579721
Apoptosis	26.67	14.92	9	14827	402	34941693
Drug abuse	26.46	14.92	5	14831	99091	34843004
Probiotic therapy	26.45	14.92	7	14829	133	34941962
Fear	26.17	14.92	27	14809	10449	34931646
Maculopathy	25.82	14.92	11	14825	935	34941160
Renal graft infection	25.49	14.92	8	14828	283	34941812
Cardiomegaly	25.33	14.92	32	14804	15406	34926689
Atelectasis	24.83	14.92	34	14802	17693	34924402
Scoliosis	24.26	14.92	15	14821	2778	34939317
Visual acuity reduced	24.19	14.92	32	14804	16117	34925978
Dysphagia	23.63	14.92	69	14767	62312	34879783
Rotavirus infection	22.90	14.92	8	14828	397	34941698
Acute hepatic failure	22.81	14.92	29	14807	14045	34928050
Fluid intake reduced	22.71	14.92	16	14820	3685	34938410
Demyelination	22.31	14.92	15	14821	3206	34938889
Acute pulmonary oedema	22.19	14.92	21	14815	7322	34934773
Ascites	22.13	14.92	56	14780	46515	34895580
Acute generalised exanthematous pustulosis	21.67	14.92	20	14816	6756	34935339
Platelet count decreased	21.54	14.92	12	14824	119705	34822390
Product dose omission issue	21.54	14.92	12	14824	119699	34822396
Fibrinolysis increased	21.28	14.92	4	14832	13	34942082
Cerebral ischaemia	20.88	14.92	19	14817	6303	34935792
Atheroembolism	20.52	14.92	7	14829	323	34941772
Nosocomial infection	20.36	14.92	10	14826	1181	34940914
Labelled drug-drug interaction medication error	19.94	14.92	28	14808	14911	34927184
Systemic infection	19.89	14.92	17	14819	5195	34936900
Productive cough	19.59	14.92	47	14789	37766	34904329
Shock	19.47	14.92	36	14800	24143	34917952
Respiratory symptom	19.12	14.92	11	14825	1786	34940309
Circulatory collapse	19.09	14.92	33	14803	21005	34921090
Fatigue	18.95	14.92	87	14749	370566	34571529
Weight increased	18.75	14.92	8	14828	93025	34849070
Erythema	18.74	14.92	81	14755	88699	34853396
Escherichia urinary tract infection	18.73	14.92	14	14822	3532	34938563
Genitourinary tract infection	18.42	14.92	5	14831	105	34941990
Mechanical ventilation	18.19	14.92	11	14825	1959	34940136
Urticaria	18.14	14.92	63	14773	62314	34879781
Pneumococcal infection	18.05	14.92	7	14829	467	34941628
Mastocytosis	17.97	14.92	4	14832	35	34942060
Lip ulceration	17.92	14.92	8	14828	761	34941334
Retinopathy	17.71	14.92	11	14825	2053	34940042
Blood pressure decreased	17.64	14.92	55	14781	51460	34890635
Dyspnoea	17.58	14.92	240	14596	376542	34565553
Bronchopneumopathy	17.53	14.92	7	14829	505	34941590
Patent ductus arteriosus	17.18	14.92	13	14823	3341	34938754
Malignant neoplasm progression	17.07	14.92	8	14828	88038	34854057
Pseudomembranous colitis	16.98	14.92	12	14824	2779	34939316
Venous thrombosis	16.91	14.92	13	14823	3422	34938673
Foetal growth restriction	16.89	14.92	14	14822	4103	34937992
Lymphangitis	16.86	14.92	7	14829	558	34941537
Serratia infection	16.79	14.92	8	14828	884	34941211
Optic atrophy	16.60	14.92	8	14828	906	34941189
Insomnia	16.52	14.92	12	14824	103895	34838200
Normochromic normocytic anaemia	16.39	14.92	14	14822	4273	34937822
Multiple organ dysfunction syndrome	16.26	14.92	70	14766	76496	34865599
Retinal haemorrhage	16.24	14.92	15	14821	5074	34937021
Cross sensitivity reaction	16.08	14.92	9	14827	1388	34940707
Endotracheal intubation	15.97	14.92	12	14824	3053	34939042
Arthralgia	15.89	14.92	30	14806	170011	34772084
Acquired haemophilia	15.84	14.92	8	14828	1002	34941093
Pneumonectomy	15.70	14.92	4	14832	65	34942030
Vesicoureteric reflux	15.57	14.92	5	14831	191	34941904
Rhinalgia	15.53	14.92	8	14828	1045	34941050
Haemorrhoids thrombosed	15.32	14.92	5	14831	201	34941894
Product preparation issue	15.31	14.92	6	14830	412	34941683
Feeling abnormal	15.24	14.92	4	14832	63231	34878864
Cerebellar stroke	14.95	14.92	5	14831	217	34941878
Blepharospasm	14.94	14.92	8	14828	1130	34940965

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic reaction	361.90	12.31	276	28954	83467	79631691
Anaphylactic shock	335.86	12.31	192	29038	35804	79679354
Type IV hypersensitivity reaction	243.94	12.31	81	29149	4000	79711158
Macular oedema	231.81	12.31	84	29146	5390	79709768
Retinal detachment	195.60	12.31	86	29144	9161	79705997
Corneal oedema	156.57	12.31	52	29178	2568	79712590
Rash maculo-papular	139.87	12.31	135	29095	55943	79659215
Drug reaction with eosinophilia and systemic symptoms	136.93	12.31	142	29088	64102	79651056
Retinal toxicity	130.14	12.31	39	29191	1372	79713786
Bronchospasm	118.52	12.31	87	29143	24772	79690386
Retinal oedema	117.05	12.31	33	29197	932	79714226
Retinal infarction	108.62	12.31	23	29207	183	79714975
Endophthalmitis	108.21	12.31	51	29179	6377	79708781
Lung consolidation	106.24	12.31	56	29174	8891	79706267
Resuscitation	98.46	12.31	36	29194	2368	79712790
Anterior chamber inflammation	89.90	12.31	24	29206	550	79714608
Clostridium difficile infection	86.73	12.31	92	29138	42593	79672565
Corneal opacity	84.68	12.31	26	29204	994	79714164
Soft tissue mass	82.74	12.31	27	29203	1261	79713897
Visual acuity reduced	77.35	12.31	73	29157	29396	79685762
Multimorbidity	75.88	12.31	26	29204	1413	79713745
Ocular toxicity	75.45	12.31	23	29207	858	79714300
Oesophageal perforation	73.65	12.31	26	29204	1545	79713613
Kounis syndrome	69.10	12.31	33	29197	4249	79710909
Spinal muscular atrophy	68.60	12.31	18	29212	385	79714773
Type I hypersensitivity	68.26	12.31	33	29197	4365	79710793
Macular detachment	68.23	12.31	16	29214	211	79714947
Clostridium difficile colitis	66.32	12.31	70	29160	32213	79682945
Exposure during pregnancy	61.72	12.31	123	29107	101009	79614149
Toxic epidermal necrolysis	60.32	12.31	78	29152	44503	79670655
Joint swelling	59.72	12.31	16	29214	288630	79426528
Tachypnoea	59.69	12.31	66	29164	31997	79683161
Stoma closure	58.41	12.31	15	29215	294	79714864
Cross sensitivity reaction	58.05	12.31	28	29202	3684	79711474
Accidental overdose	57.91	12.31	72	29158	39509	79675649
Pneumococcal sepsis	57.52	12.31	22	29208	1640	79713518
Corneal deposits	55.76	12.31	16	29214	482	79714676
Pyrexia	53.55	12.31	428	28802	678281	79036877
Circulatory collapse	52.68	12.31	67	29163	37601	79677557
Transplant failure	52.14	12.31	28	29202	4613	79710545
Superinfection	50.70	12.31	28	29202	4874	79710284
Infusion related reaction	49.08	12.31	12	29218	230225	79484933
Pathogen resistance	48.49	12.31	41	29189	14301	79700857
Multiple organ dysfunction syndrome	48.45	12.31	124	29106	120122	79595036
Motor neurone disease	48.37	12.31	15	29215	593	79714565
Arthropathy	47.16	12.31	5	29225	177106	79538052
Cystoid macular oedema	47.06	12.31	20	29210	1960	79713198
Fatigue	46.34	12.31	180	29050	929547	78785611
Rheumatoid arthritis	46.15	12.31	10	29220	208460	79506698
Weight increased	46.11	12.31	22	29208	277364	79437794
Rales	45.84	12.31	46	29184	19955	79695203
Pseudomembranous colitis	45.66	12.31	27	29203	5347	79709811
Inflammatory marker increased	43.26	12.31	34	29196	10706	79704452
Maculopathy	43.25	12.31	21	29209	2804	79712354
Urticaria	42.66	12.31	157	29073	185044	79530114
Renal injury	42.65	12.31	41	29189	16886	79698272
Alopecia	42.20	12.31	16	29214	231339	79483819
Dysbiosis	41.70	12.31	16	29214	1203	79713955
Anticoagulation drug level above therapeutic	41.12	12.31	22	29208	3598	79711560
Nosocomial infection	40.21	12.31	20	29210	2812	79712346
Drug abuse	39.90	12.31	6	29224	162685	79552473
Cataract operation complication	39.74	12.31	11	29219	290	79714868
Respiratory tract infection bacterial	39.70	12.31	18	29212	2059	79713099
Pneumonia	38.97	12.31	391	28839	659855	79055303
Angioedema	38.83	12.31	86	29144	75949	79639209
Pneumonia mycoplasmal	38.71	12.31	16	29214	1462	79713696
Premature rupture of membranes	38.71	12.31	22	29208	4047	79711111
Blood pressure decreased	38.44	12.31	101	29129	99365	79615793
Drug interaction	38.39	12.31	272	28958	414911	79300247
Premature delivery	38.09	12.31	45	29185	23422	79691736
Lower respiratory tract infection bacterial	37.98	12.31	14	29216	942	79714216
Lymphadenectomy	37.69	12.31	15	29215	1244	79713914
Parophthalmia	36.73	12.31	11	29219	386	79714772
Myocardial ischaemia	36.65	12.31	46	29184	25473	79689685
Bronchial disorder	36.60	12.31	18	29212	2471	79712687
Arthralgia	36.55	12.31	99	29131	571704	79143454
Ischaemic cerebral infarction	36.28	12.31	18	29212	2517	79712641
Fall	36.23	12.31	78	29152	487551	79227607
Oesophageal carcinoma	36.07	12.31	31	29199	11053	79704105
Musculoskeletal stiffness	35.61	12.31	10	29220	174998	79540160
Death	35.52	12.31	99	29131	566415	79148743
Anterior chamber fibrin	35.51	12.31	9	29221	167	79714991
Intestinal intraepithelial lymphocytes increased	35.31	12.31	9	29221	171	79714987
Increased bronchial secretion	34.40	12.31	19	29211	3308	79711850
Airway peak pressure increased	33.80	12.31	10	29220	336	79714822
Retinal disorder	33.71	12.31	16	29214	2031	79713127
Pulmonary vasculitis	33.42	12.31	12	29218	749	79714409
Stevens-Johnson syndrome	33.26	12.31	55	29175	39111	79676047
Intestinal ischaemia	33.16	12.31	32	29198	13238	79701920
Face oedema	33.12	12.31	46	29184	28090	79687068
Immunosuppressant drug level increased	33.00	12.31	27	29203	9000	79706158
Shock	32.83	12.31	58	29172	43490	79671668
Erythema	31.95	12.31	164	29066	223126	79492032
Fibrinolysis increased	31.44	12.31	6	29224	26	79715132
Probiotic therapy	31.39	12.31	8	29222	152	79715006
Brain injury	31.12	12.31	29	29201	11488	79703670
Sputum increased	31.11	12.31	20	29210	4593	79710565
Cryptitis	30.81	12.31	9	29221	289	79714869
Sepsis	30.64	12.31	186	29044	269242	79445916
Trimethylaminuria	29.78	12.31	8	29222	188	79714970
Chest X-ray abnormal	29.71	12.31	24	29206	7859	79707299
Eye inflammation	29.56	12.31	22	29208	6391	79708767
Pain	29.08	12.31	146	29084	703656	79011502
Fear	29.01	12.31	38	29192	21948	79693210
Therapeutic product effect decreased	28.78	12.31	12	29218	163851	79551307
Microvillous inclusion disease	28.68	12.31	8	29222	217	79714941
Metabolic disorder	28.53	12.31	25	29205	9145	79706013
Systemic lupus erythematosus	28.51	12.31	5	29225	121144	79594014
Lack of spontaneous speech	28.37	12.31	8	29222	226	79714932
Drug intolerance	28.37	12.31	33	29197	264086	79451072
Vulval cancer metastatic	27.65	12.31	4	29226	0	79715158
Treatment failure	27.59	12.31	14	29216	170472	79544686
Disease complication	27.49	12.31	19	29211	4918	79710240
Meningitis candida	27.27	12.31	7	29223	137	79715021
Cardiac massage	26.72	12.31	5	29225	19	79715139
Cutaneous vasculitis	26.69	12.31	23	29207	8229	79706929
Apoptosis	25.89	12.31	9	29221	511	79714647
Hypersensitivity vasculitis	25.87	12.31	21	29209	6922	79708236
Joint hyperextension	25.63	12.31	8	29222	323	79714835
Pericarditis	25.20	12.31	4	29226	104232	79610926
Renal failure	24.94	12.31	142	29088	200826	79514332
Boutonneuse fever	24.88	12.31	4	29226	4	79715154
Gait disturbance	24.42	12.31	24	29206	207482	79507676
Injury	24.34	12.31	73	29157	77423	79637735
Toxic skin eruption	24.10	12.31	35	29195	22258	79692900
Intentional product use issue	23.86	12.31	13	29217	152099	79563059
Haemoptysis	23.85	12.31	59	29171	55940	79659218
Neuritis	23.74	12.31	12	29218	1746	79713412
Serratia infection	23.62	12.31	12	29218	1764	79713394
Vitreous disorder	23.15	12.31	7	29223	254	79714904
Bulimia nervosa	23.12	12.31	7	29223	255	79714903
Serous retinal detachment	23.11	12.31	10	29220	1024	79714134
Tachycardia	22.98	12.31	127	29103	177641	79537517
Nephritis allergic	22.91	12.31	9	29221	721	79714437
Cardiovascular insufficiency	22.80	12.31	14	29216	2967	79712191
Oliguria	22.78	12.31	29	29201	16280	79698878
Ascites	22.63	12.31	70	29160	75492	79639666
Biopsy	22.63	12.31	9	29221	745	79714413
Pain in extremity	22.59	12.31	64	29166	364474	79350684
Labelled drug-drug interaction medication error	22.37	12.31	38	29192	27612	79687546
Abdominal discomfort	22.22	12.31	36	29194	250691	79464467
Escherichia infection	22.02	12.31	30	29200	17987	79697171
Renal graft infection	21.65	12.31	8	29222	542	79714616
Acute generalised exanthematous pustulosis	21.50	12.31	29	29201	17225	79697933
Toxoplasmosis	21.49	12.31	13	29217	2684	79712474
Endotracheal intubation	21.39	12.31	16	29214	4681	79710477
Venous thrombosis	21.34	12.31	19	29211	7097	79708061
Atheroembolism	21.24	12.31	7	29223	337	79714821
Platelet count decreased	21.24	12.31	24	29206	194640	79520518
Contraindicated product administered	21.24	12.31	16	29214	157522	79557636
Exophthalmos	21.02	12.31	11	29219	1719	79713439
Cardiac arrest	20.95	12.31	121	29109	171975	79543183
Oesophageal spasm	20.91	12.31	14	29216	3442	79711716
Retinal haemorrhage	20.88	12.31	20	29210	8197	79706961
Antidiuretic hormone abnormality	20.72	12.31	5	29225	75	79715083
Aspergillus infection	20.59	12.31	30	29200	19131	79696027
Lip swelling	20.57	12.31	46	29184	40865	79674293
Injection site pain	20.50	12.31	11	29219	129827	79585331
Nasopharyngitis	20.19	12.31	39	29191	253842	79461316
Insomnia	20.08	12.31	37	29193	245133	79470025
Anhedonia	20.04	12.31	26	29204	14872	79700286
Toxicity to various agents	20.02	12.31	83	29147	421457	79293701
Delayed delivery	20.02	12.31	4	29226	23	79715135
Vanishing twin syndrome	19.98	12.31	5	29225	88	79715070
Optic atrophy	19.88	12.31	11	29219	1922	79713236
Sepsis syndrome	19.45	12.31	10	29220	1507	79713651
Transaminases increased	19.43	12.31	52	29178	51691	79663467
Demyelination	19.40	12.31	19	29211	8004	79707154
Delivery	19.33	12.31	8	29222	734	79714424
Rotavirus infection	19.33	12.31	8	29222	734	79714424
Discomfort	19.32	12.31	11	29219	125606	79589552
Macular ischaemia	19.28	12.31	5	29225	102	79715056
Hypopyon	19.03	12.31	9	29221	1133	79714025
Wrong technique in product usage process	19.02	12.31	65	29165	73810	79641348
Intraocular pressure increased	18.97	12.31	20	29210	9185	79705973
Conjunctival oedema	18.91	12.31	9	29221	1149	79714009
Clostridium test positive	18.90	12.31	17	29213	6437	79708721
Rash	18.83	12.31	307	28923	578051	79137107
Skin test positive	18.80	12.31	9	29221	1165	79713993
Toxic anterior segment syndrome	18.68	12.31	12	29218	2752	79712406
Acinetobacter infection	18.63	12.31	12	29218	2765	79712393
Blood cholesterol increased	18.55	12.31	4	29226	83716	79631442
Drug resistance	18.53	12.31	45	29185	42168	79672990
Oesophageal pain	18.22	12.31	14	29216	4265	79710893
Tubulointerstitial nephritis	18.13	12.31	42	29188	38193	79676965
Emotional distress	17.96	12.31	43	29187	39926	79675232
Acute hepatic failure	17.61	12.31	36	29194	30077	79685081
Drug hypersensitivity	17.54	12.31	177	29053	298739	79416419
Product preparation issue	17.23	12.31	9	29221	1401	79713757
Cardiomegaly	17.21	12.31	33	29197	26319	79688839
Retinopathy	17.16	12.31	13	29217	3878	79711280
Hypotension	17.13	12.31	241	28989	440076	79275082
Pruritus	16.99	12.31	220	29010	394428	79320730
Intentional product misuse	16.65	12.31	7	29223	95158	79620000
Mediastinal effusion	16.58	12.31	4	29226	60	79715098
Natural killer cell count decreased	16.58	12.31	4	29226	60	79715098
Arteriospasm coronary	16.41	12.31	16	29214	6700	79708458
Mechanical ventilation	16.25	12.31	11	29219	2753	79712405
Cardiopulmonary failure	16.24	12.31	16	29214	6785	79708373
Deafness bilateral	16.05	12.31	10	29220	2175	79712983
Klebsiella infection	16.01	12.31	24	29206	15696	79699462
Hepatosplenomegaly	15.86	12.31	15	29215	6054	79709104
Hypertension	15.81	12.31	65	29165	330927	79384231
Bronchopneumopathy	15.56	12.31	7	29223	786	79714372
Visual impairment	15.55	12.31	71	29159	92060	79623098
Renal impairment	15.49	12.31	105	29125	157678	79557480
Live birth	15.48	12.31	26	29204	18718	79696440
Hydronephrosis	15.48	12.31	25	29205	17429	79697729
Wound	15.40	12.31	12	29218	116167	79598991
Coma blister	15.27	12.31	5	29225	236	79714922
Drug-induced liver injury	15.16	12.31	56	29174	66061	79649097
Haemorrhoids thrombosed	15.03	12.31	5	29225	248	79714910
Linear IgA disease	15.01	12.31	11	29219	3121	79712037
White blood cell count decreased	14.90	12.31	29	29201	188259	79526899
Pneumonectomy	14.89	12.31	4	29226	94	79715064
Acute pulmonary oedema	14.89	12.31	22	29208	14208	79700950
Atelectasis	14.82	12.31	35	29195	32222	79682936
Systemic infection	14.68	12.31	18	29212	9734	79705424
Leukocytosis	14.66	12.31	42	29188	43413	79671745
Cyanosis	14.60	12.31	30	29200	25152	79690006
Dyspnoea	14.59	12.31	414	28816	856611	78858547
Bladder neck obstruction	14.47	12.31	4	29226	105	79715053
Genitourinary tract infection	14.45	12.31	5	29225	280	79714878
Lymphangitis	14.44	12.31	8	29222	1400	79713758
Blindness	14.37	12.31	32	29198	28351	79686807
Product monitoring error	14.32	12.31	17	29213	8889	79706269
Headache	14.31	12.31	162	29068	653610	79061548
Motor dysfunction	14.31	12.31	22	29208	14711	79700447
Pneumococcal infection	14.30	12.31	7	29223	951	79714207
Pneumonia klebsiella	14.18	12.31	13	29217	5041	79710117
Brain compression	14.18	12.31	6	29224	582	79714576
Urticaria contact	14.04	12.31	3	29227	25	79715133
Anti factor V antibody positive	14.04	12.31	3	29227	25	79715133
Inappropriate schedule of product administration	14.01	12.31	17	29213	133611	79581547
Blood pressure increased	13.91	12.31	36	29194	211324	79503834
Weight decreased	13.88	12.31	75	29155	355123	79360035
Blood glucose increased	13.87	12.31	13	29217	114962	79600196
Erosive duodenitis	13.84	12.31	9	29221	2108	79713050
Neuropathy peripheral	13.76	12.31	19	29211	141286	79573872
Moraxella infection	13.71	12.31	6	29224	631	79714527
HER2 positive breast cancer	13.61	12.31	5	29225	333	79714825
Eosinophilia	13.57	12.31	42	29188	45303	79669855
Fluid intake reduced	13.56	12.31	14	29216	6274	79708884
Cholestasis	13.54	12.31	46	29184	52063	79663095
Contusion	13.51	12.31	21	29209	148755	79566403
Anaphylactoid reaction	13.41	12.31	13	29217	5409	79709749
Rash erythematous	13.30	12.31	49	29181	57720	79657438
Scoliosis	13.26	12.31	15	29215	7449	79707709
B-lymphocyte count increased	13.18	12.31	4	29226	147	79715011
Mucosal erosion	13.09	12.31	9	29221	2309	79712849
Drug level increased	13.07	12.31	38	29192	39613	79675545
Respiratory failure	13.05	12.31	112	29118	180799	79534359
Amaurosis	12.86	12.31	7	29223	1184	79713974
Peripheral swelling	12.84	12.31	53	29177	269564	79445594
Cerebral ischaemia	12.72	12.31	18	29212	11177	79703981
Cholestatic liver injury	12.51	12.31	12	29218	4929	79710229
Decreased appetite	12.46	12.31	74	29156	342344	79372814
Pupillary block	12.37	12.31	3	29227	46	79715112

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DC02	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Second-generation cephalosporins
ATC	J01RA03	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials
ATC	S01AA27	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics
FDA CS	M0003827	Cephalosporins
FDA EPC	N0000175488	Cephalosporin Antibacterial
CHEBI has role	CHEBI:88188	allergenic drug
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Streptococcal meningitis	indication	4510004	DOID:11574
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Staphylococcal meningitis	indication	12166008
Gonorrhea	indication	15628003	DOID:7551
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Staphylococcal pneumonia	indication	22754005
Lyme disease	indication	23502006	DOID:11729
Streptococcal septicemia	indication	29577008
Acute gonococcal urethritis	indication	29864006
Pneumonia due to Streptococcus	indication	34020007
Streptococcal tonsillitis	indication	41582007
Gonorrhea of rectum	indication	42746002
Impetigo	indication	48277006	DOID:8504
Lower respiratory tract infection	indication	50417007
Pneumonia due to Escherichia coli	indication	51530003
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Acute gonococcal endometritis	indication	65295003	DOID:7527
Acute maxillary sinusitis	indication	68272006	DOID:2050
Haemophilus influenzae pneumonia	indication	70036007
Infection due to Escherichia coli	indication	71057007
Rhinoscleroma	indication	72409005	DOID:11336
Gonorrhea of pharynx	indication	74372003
Acute bacterial sinusitis	indication	75498004
Bacterial meningitis	indication	95883001	DOID:9470
Infection of bone	indication	111253001
Staphylococcal septicemia	indication	111821004
Infection due to Enterobacteriaceae	indication	128945009
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Escherichia coli urinary tract infection	indication	301011002
Streptococcus pyogenes infection	indication	302809008
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Infectious disorder of joint	indication	363162000
Infection due to Staphylococcus aureus	indication	406602003
Acute exacerbation of chronic bronchitis	indication	425748003
Osteomyelitis due to Staphylococcus aureus	indication	428783003
Moraxella Catarrhalis Acute Otitis Media	indication	703469002
Haemophilus Influenzae Bronchitis	indication
Streptococcus Pneumoniae Chronic Bronchitis	indication
Disseminated Gonococcal Infection	indication
Streptococcus Pneumoniae Bronchitis	indication
Haemophilus Parainfluenzae Bronchitis	indication
Staphylococcus Aureus Joint Infection	indication
H. Influenzae Meningitis	indication
Prevention of Perioperative Infection	indication
Haemophilus Influenzae Chronic Bronchitis	indication
Haemophilus Septicemia	indication
Haemophilus Parainfluenzae Chronic Bronchitis	indication
Open Heart Surgery Infection Prevention	indication
Pyrexia of unknown origin	off-label use	7520000
Sepsis of the newborn	off-label use	206376005
Neonatal pneumonia	off-label use	233619008
Neonatal meningitis	off-label use	276674008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Factor II deficiency	contraindication	73975000
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.32	acidic
pKa2	13.33	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Carbonic anhydrase 2	Enzyme	P00918	CAH2_HUMAN		IC50	5.92		WOMBAT-PK
72 kDa type IV collagenase	Enzyme	P08253	MMP2_HUMAN		IC50	4.37		WOMBAT-PK
Matrix metalloproteinase-9	Enzyme	P14780	MMP9_HUMAN		IC50	4.96		WOMBAT-PK
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL
Penicillin-binding protein 1A	Enzyme		PBPA_CLOPE					WOMBAT-PK

External reference:

ID	Source
4019668	VUID
N0000147760	NUI
D00262	KEGG_DRUG
56238-63-2	SECONDARY_CAS_RN
204144	RXNORM
C0007562	UMLSCUI
CHEBI:3515	CHEBI
KOV	PDB_CHEM_ID
CHEMBL2146124	ChEMBL_ID
CHEMBL1436	ChEMBL_ID
D002444	MESH_DESCRIPTOR_UI
DB01112	DRUGBANK_ID
5479529	PUBCHEM_CID
10900	IUPHAR_LIGAND_ID
3902	INN_ID
O1R9FJ93ED	UNII
2973	MMSL
4389	MMSL
d00056	MMSL
002731	NDDF
003590	NDDF
372833007	SNOMEDCT_US
48753004	SNOMEDCT_US
73986003	SNOMEDCT_US
4017551	VANDF
4019668	VANDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9567	INJECTION, POWDER, FOR SOLUTION	1.50 g	INTRAVENOUS	ANDA	23 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9567	INJECTION, POWDER, FOR SOLUTION	1.50 g	INTRAVENOUS	ANDA	23 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9568	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAMUSCULAR	ANDA	23 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9568	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAMUSCULAR	ANDA	23 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9569	INJECTION, POWDER, FOR SOLUTION	7.50 g	INTRAVENOUS	ANDA	24 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9976	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAVENOUS	ANDA	24 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9976	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAVENOUS	ANDA	24 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9977	INJECTION, POWDER, FOR SOLUTION	1.50 g	INTRAVENOUS	ANDA	22 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9977	INJECTION, POWDER, FOR SOLUTION	1.50 g	INTRAVENOUS	ANDA	22 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9979	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAMUSCULAR	ANDA	22 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9979	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAMUSCULAR	ANDA	22 sections
Cefuroxime and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3112	INJECTION, SOLUTION	750 mg	INTRAVENOUS	NDA	24 sections
Cefuroxime and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0264-3114	INJECTION, SOLUTION	1.50 g	INTRAVENOUS	NDA	24 sections
Cefuroxime sodium	HUMAN PRESCRIPTION DRUG LABEL	1	25021-118	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAVENOUS	ANDA	25 sections
Cefuroxime sodium	HUMAN PRESCRIPTION DRUG LABEL	1	25021-119	INJECTION, POWDER, FOR SOLUTION	1.50 g	INTRAVENOUS	ANDA	25 sections
Cefuroxime sodium	HUMAN PRESCRIPTION DRUG LABEL	1	25021-182	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAVENOUS	ANDA	26 sections
Cefuroxime sodium	HUMAN PRESCRIPTION DRUG LABEL	1	25021-183	INJECTION, POWDER, FOR SOLUTION	1.50 g	INTRAVENOUS	ANDA	26 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-710	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAMUSCULAR	ANDA	24 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-711	INJECTION, POWDER, FOR SOLUTION	1.50 g	INTRAVENOUS	ANDA	24 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-712	INJECTION, POWDER, FOR SOLUTION	7.50 g	INTRAVENOUS	ANDA	25 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-720	INJECTION, POWDER, FOR SOLUTION	750 mg	INTRAVENOUS	ANDA	24 sections
Cefuroxime	HUMAN PRESCRIPTION DRUG LABEL	1	44567-722	INJECTION, POWDER, FOR SOLUTION	1.50 g	INTRAVENOUS	ANDA	24 sections